Views: 0 Author: Site Editor Publish Time: 2026-11-06 Origin: Site
The global vitamin K2 market is projected to grow from USD 179 million in 2026 to USD 339.9 million by 2031, according to MarketsandMarkets' 2026 Vitamin K2 Market report. For supplement manufacturers, this growth raises a practical question: which vitamin K2 ingredient format is best suited to the products they want to develop?
Vitamin K2 Oil (MCT) combines menaquinone-7 (MK-7), a form of vitamin K2, with a medium-chain triglyceride carrier. This oil-based format is particularly relevant to softgels, oral drops, and selected vitamin D3+K2 formulations.
GEMSEN supplies Vitamin K2 Oil (MCT), CAS 2124-57-4 in several listed concentrations. Beyond general nutritional benefits, manufacturers need to understand its clinical evidence, all-trans MK-7 quality, carrier compatibility, and practical formulation requirements.
Vitamin K2 has become an increasingly familiar ingredient in bone-health and healthy-aging supplements. At the same time, supplement brands are exploring formats beyond conventional tablets, including liquid drops and oil-filled capsules.
Market research suggests that this shift is creating opportunities for oil-based ingredient systems.
MK-7 has attracted interest because of its role in vitamin K-dependent protein activation and its relatively long circulating half-life compared with certain other forms of vitamin K.
The 2026 MarketsandMarkets report identifies MK-7 as the leading vitamin K2 product type and forecasts a 13.7% compound annual growth rate for the overall vitamin K2 market through 2031.
Meanwhile, Mordor Intelligence's Vitamin K2 Market analysis projects oil-based vitamin K2 systems to grow at a 12.92% CAGR through 2031, making them the fastest-growing formulation segment in its forecast.
These are projections from separate market-research firms, rather than guaranteed future sales. Nevertheless, they indicate commercial interest in MK-7 ingredients that can be incorporated into different supplement formats.
The physical form of an ingredient influences which products can be developed efficiently.
MK-7 is fat-soluble, making an appropriate lipid carrier useful in formulations that already contain an oil phase. An MK-7 oil ingredient can therefore be considered for softgel fills, liquid drops, and selected combination products.
However, the choice of carrier should reflect the intended formulation. An oil-based ingredient is not automatically suitable for clear water-based beverages or dry powder blends.
This distinction is important for supplement manufacturers seeking to expand their product range without creating unnecessary formulation difficulties.
Vitamin K is required for the carboxylation of several proteins involved in normal physiological functions, including blood coagulation and bone metabolism.
MK-7 is one of the vitamin K2 forms investigated in human supplementation studies. Its biological mechanisms are reasonably well established, but clinical outcomes differ between populations and studies.
For ingredient suppliers and supplement brands, this distinction should guide how health-related information is presented.
Vitamin K acts as a cofactor for gamma-glutamyl carboxylase, an enzyme involved in activating proteins such as osteocalcin.
Osteocalcin is present in bone tissue and participates in normal bone metabolism. Its vitamin K-dependent carboxylation affects its ability to interact with calcium and the bone mineral matrix.
A 2013 randomized controlled trial published in Osteoporosis International investigated 180 μg of MK-7 daily in 244 healthy postmenopausal women over three years. Researchers reported that supplementation slowed age-related declines in certain measurements of bone mineral density and bone strength.
However, the clinical evidence is not uniformly positive. A 2021 randomized trial involving 142 postmenopausal women with osteopenia found that MK-7 supplementation improved osteocalcin carboxylation but did not significantly improve bone mineral density or bone microarchitecture compared with placebo over three years.
These findings support a careful distinction between vitamin K's established role in bone metabolism and the less certain extent of additional clinical benefit from MK-7 supplementation in different populations.
Matrix Gla protein (MGP) is another vitamin K-dependent protein. It is involved in the regulation of mineralization in vascular tissues, and its biological activity depends on vitamin K-dependent carboxylation.
This relationship has encouraged researchers to investigate whether MK-7 supplementation can influence vascular calcification.
A 2026 randomized clinical trial published in JAMA Cardiology investigated MK-7 supplementation in 180 randomized patients with symptomatic coronary artery disease and existing coronary artery calcification.
Participants were assigned to receive either 360 μg of MK-7 daily or a placebo for two years. The study found significantly slower progression of coronary artery calcification in the MK-7 group compared with placebo (P=0.02).
However, the researchers emphasized that additional studies are necessary to determine whether these findings translate into meaningful reductions in cardiovascular events.
The results are therefore relevant to ongoing MK-7 research, but they do not establish that vitamin K2 supplements prevent heart disease, reverse arterial calcification, or reduce heart attacks.
Importantly, this was a study of MK-7 supplementation, not a clinical trial of GEMSEN's specific Vitamin K2 Oil (MCT) product.
MCT oil provides a lipid-based environment for fat-soluble compounds such as MK-7.
For supplement manufacturers, its value lies primarily in formulation compatibility, ingredient handling, and its suitability for selected oil-based products.
MK-7 is a lipophilic molecule, meaning it is more compatible with suitable lipid environments than with water.
An MCT-based ingredient can provide MK-7 in a preformulated oil phase, which may simplify its incorporation into products such as softgels and oral drops.
This is particularly relevant when only a small amount of MK-7 is required per serving and the manufacturer must distribute it consistently throughout the finished formulation.
However, MCT oil should not be described as universally superior to all other carrier oils. Bioavailability depends on the complete formulation, digestion conditions, and other factors.
The practical advantage of MCT is that it offers a useful formulation option for products designed around an oil phase.
A suitable carrier is only one part of ensuring the quality of a vitamin K2 supplement.
Manufacturers must also assess how MK-7 responds to processing, light, temperature, oxygen exposure, packaging, and interaction with other ingredients.
Because MK-7 is commonly incorporated in microgram amounts per serving, ingredient concentration and mixing consistency are particularly important.
A formulation should be evaluated for active-content uniformity at production and throughout the intended shelf life. The presence of MCT oil alone does not guarantee stability or accurate dosing.
The most suitable applications for Vitamin K2 Oil (MCT) are those where the formulation contains a compatible lipid phase.
Different formats have different manufacturing requirements, so ingredient selection should begin with the finished product.
Softgel capsules are a common delivery format for fat-soluble nutritional ingredients.
Vitamin K2 Oil (MCT) can be evaluated as part of an oil-based softgel filling formulation. Manufacturers should consider the concentration of MK-7, target fill weight, shell compatibility, manufacturing conditions, and finished-product stability.
For brands developing combination supplements, the ingredient may also be considered alongside other compatible oil-soluble nutrients.
The suitability of the complete fill must be established through formulation and stability testing rather than assumed from the individual ingredients.
Liquid vitamin K2 drops are another relevant application for an MCT-based ingredient.
These products allow manufacturers to develop oil-based supplements using a controlled liquid serving format.
However, accurate dosing is particularly important. The MK-7 concentration, final product viscosity, dispensing system, and packaging design all influence the amount delivered per serving.
Manufacturers should evaluate dose uniformity and stability under the intended storage and use conditions.
Vitamin D3 and vitamin K2 are frequently considered together in supplement development because both participate in physiological processes related to bone health.
Vitamin D contributes to calcium absorption and normal calcium metabolism, while vitamin K is involved in the activation of proteins required for normal bone metabolism.
Because both vitamins are fat-soluble, an oil-based formulation can provide a practical means of incorporating them into a shared lipid phase.
GEMSEN also lists vitamin D3 raw materials within its nutritional ingredient range.
A successful D3+K2 formulation still requires compatibility and stability testing for both active ingredients. Their inclusion in one product does not automatically establish superior clinical outcomes or guaranteed synergy.
Vitamin K2 Oil (MCT) may also be evaluated for selected functional-food applications where a suitable lipid phase is available.
Examples include certain fat-containing nutritional products and appropriately designed fortified foods.
However, oil-based MK-7 is not a direct substitute for water-dispersible MK-7 powder in every product.
Clear beverages, dry mixes, and some low-fat matrices may require different delivery technologies, such as an appropriate emulsion or encapsulated ingredient.
For manufacturers, identifying these limitations early can prevent unnecessary reformulation work.
Raw material quality is a major consideration when selecting vitamin K2 for commercial supplement production.
MK-7 can exist in different geometric isomer configurations. The all-trans form is particularly relevant because research has demonstrated greater carboxylation activity than cis forms.
A 2022 study comparing trans and cis MK-7 reported higher carboxylative activity for trans MK-7, while observing limited activity from cis MK-7 under the experimental conditions.
For buyers, the important issue is whether the supplier's analytical documentation adequately identifies the relevant MK-7 content and isomer profile.
The term all-trans describes the arrangement of MK-7's molecular structure.
An ingredient may be described as high in all-trans MK-7, but the claim should be supported by an appropriate analytical specification and batch results.
GEMSEN's Vitamin K2 Oil (MCT) product page describes an all-trans MK-7 ingredient produced through natural fermentation. Its published specification also lists a cis-menaquinone-7 limit of no more than 2%.
For procurement purposes, buyers should request a certificate of analysis showing the applicable isomer specifications and actual batch results.
Descriptions such as “100% all-trans” should not be treated as verified batch purity figures unless the analytical data support that exact claim.
A certificate of analysis helps buyers compare delivered material with the agreed technical specification.
For MK-7 oil, important information may include the assay, relevant isomer profile, carrier composition, microbiological requirements, and applicable contaminant limits.
The analytical method also matters. Buyers should confirm what the assay measures and whether the reported results distinguish the relevant MK-7 components.
This can be particularly important when comparing suppliers offering different concentrations or ingredient sources.
Supplement brands and contract manufacturers need ingredient specifications that are relevant to their production process.
Before purchasing bulk vitamin K2 oil, buyers should confirm the target concentration, quality documentation, application requirements, and intended market.
GEMSEN's product page lists four concentration options:
Listed MK-7 Concentration | Equivalent Percentage |
|---|---|
2,000 ppm | 0.2% |
2,500 ppm | 0.25% |
10,000 ppm | 1% |
100,000 ppm | 10% |
These concentrations come from GEMSEN's published product listing. Buyers should confirm the technical specification and available supply conditions for the exact concentration required.
The same product page also includes a specification table with an MK-7 assay of at least 10,000 μg/g. This value should not be assumed to apply to the lower-concentration variants without confirmation.
A higher-concentration ingredient may reduce the amount of oil required to deliver the intended MK-7 quantity, but it can also increase the importance of accurate dilution and mixing.
In addition to concentration, buyers should evaluate the relevant safety documentation and the product's suitability for the intended market.
A 2025 safety assessment published by the Council for Responsible Nutrition reviewed more than 40 human clinical trials involving MK-7.
The assessment identified a supplemental Highest Observed Intake (HOI) level of 375 μg/day for adults.
This figure is a reference derived using CRN's assessment methodology. It is not a universal regulatory upper limit or an instruction to formulate every supplement at that dose.
The assessment specifically excludes people using vitamin K antagonist anticoagulants, such as warfarin. According to the NIH Office of Dietary Supplements, vitamin K intake can interact with these medications.
For international supplement products, permitted ingredient use, label claims, and dosage requirements must be reviewed against the regulations of the destination market.
The growing interest in vitamin K2 creates opportunities for ingredient suppliers and finished-product brands, but commercial success also depends on differentiation and formulation quality.
Three developments are especially relevant to manufacturers.
Supplement brands increasingly need to evaluate suppliers using more than price and nominal concentration.
The MK-7 assay, isomer profile, ingredient source, batch traceability, and regulatory documentation can all affect the suitability of a raw material.
For premium supplement development, clearly defined specifications are more useful than general claims about ingredient quality or bioavailability.
Combination formulations offer manufacturers an opportunity to develop products around complementary nutritional functions.
D3+K2 products can also fit oil-based formats, allowing brands to evaluate a shared carrier for compatible fat-soluble vitamins.
However, commercial differentiation should be supported by appropriate formulation design, testing, and legally permitted claims rather than unsupported assertions about enhanced clinical effectiveness.
Liquid drops and oil-based capsules provide alternatives to traditional dry supplement formats.
According to Mordor Intelligence's market forecast, oil-based vitamin K2 systems are expected to experience relatively strong growth through 2031.
This creates opportunities for ingredient manufacturers offering consistent MK-7 concentrations and suitable oil carriers.
For brands entering these segments, the important questions remain product-market fit, manufacturing feasibility, stability, and the ability to maintain accurate dosing.
GEMSEN supplies nutritional raw materials for supplement and functional-food manufacturers.
Its Vitamin K2 Oil (MCT) product is offered in several listed MK-7 concentrations and is described as a naturally fermented MK-7 ingredient in an MCT oil carrier.
These options give supplement manufacturers a starting point for evaluating ingredients for softgels, liquid drops, and compatible oil-based formulations.
For a bulk purchasing inquiry, buyers should specify the required MK-7 concentration, intended dosage form, target market, estimated quantity, and necessary analytical documentation.
If you are developing a vitamin K2 or D3+K2 supplement, contact GEMSEN for Vitamin K2 Oil (MCT) specifications and a quotation. The relevant grade and certificate of analysis can then be reviewed against your formulation requirements.
Vitamin K2 Oil (MCT) is more than a combination of MK-7 and an edible oil. For supplement manufacturers, it offers a potential ingredient solution for selected lipid-based formulations, particularly softgels, oral drops, and D3+K2 products.
The available clinical research helps explain why MK-7 continues to attract interest, while the market forecasts suggest opportunities for more diverse supplement formats.
However, the strongest commercial decision is based on verified ingredient quality, suitable formulation design, and realistic claims supported by evidence.
For brands evaluating bulk vitamin K2 oil, the right starting point is a well-defined MK-7 specification and a formulation that can consistently meet the requirements of the finished product.